**TABLE 13:** Symptom-specific assessment and management considerations for neurologic sequelae of Long COVID

Assessment Element	Assessment Details
History	Time course of neurologic symptoms  Acute versus chronic  Static versus progressive  Medication/supplement use that may impact signs, symptoms, or assessment parameters (e.g., anticholinergic medications)
Physical exam	<ul> <li>Thorough neurological examination to identify focal neurological deficits, as indicated based on the patient's reported symptoms and associated differential diagnosis         <ul> <li>Cognition, attention/concentration, expressive and receptive speech</li> <li>Cranial nerves, strength, sensation, reflexes, coordination, gait</li> </ul> </li> <li>If concern for cognitive impairment, see Table 11 [Cognitive Table]</li> </ul>
Treatment Element	Treatment Details
Non-pharmacologic management	<ul> <li>For patients who achieve a return to ADLs, see Figure 1 for return to activity guidance.</li> <li>For patients with headaches, consider ergonomic optimization, gentle stretching, deep breathing exercises, and acupuncture</li> </ul>
Pharmacologic management	<ul> <li>Consider weaning/de-prescribing antihistamine, anticholinergic, antidepressant/anxiolytic, and muscle relaxant medications</li> <li>For rebound headaches due to regular overuse of abortive headache medications (including acetaminophen and NSAIDs), reduce use of these medications to &lt; 3 times weekly</li> <li>See Table 5 for commonly used medications for Long COVID</li> </ul>
Referral, as needed	To emergency department, if new or worsening focal neurologic deficits To physiatry or neurology, if chronic focal neurologic sequelae affecting gait, mobility, cognitive status, and/or activities of daily living To neuroimmunology, if laboratory abnormalities concerning for neuroimmune dysregulation or paraneoplastic conditions (e.g. abnormal lymphocyte or immunoglobulin levels, paraneoplastic autoantibodies) <sup>8</sup>

Abbreviations: ADLs (activities of daily living), NSAIDs (non-steroidal anti-inflammatory drugs), MRI (magnetic resonance image).

Cheng AL, Herman E, Abramoff B, et al. Multidisciplinary collaborative guidance on the assessment and treatment of patients with Long COVID: A compendium statement. PM&R. 2025; 17(6): 684-708. doi:10.1002/pmrj.13397



